ADAM9 and cervical carcinoma: We identified three FGFR3‐TACC3 fusion‐positive cases (2.6%), one GOPC‐ROS1 fusion‐positive case (0.9%), and one FGFR1‐ADAM9 fusion‐positive case (0.9%) using the STAR‐Fusion program27 in the Japanese cohort of 116 patients with cervical cancer (Table S4A).